Observational Study Links GLP-1 Medications to Reduced Fracture Risk in Type 2 Diabetes Patients

An observational study suggests GLP-1 medications, including Ozempic and Mounjaro, may lower fragility fracture risk in individuals with type 2 diabetes. The most significant reductions were noted in hip, femur, and spine fractures. While encouraging, researchers emphasize this study does not establish a causal link, and further research is necessary to confirm these findings. This potential benefit could improve long-term outcomes for diabetes patients.